CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER.
Cancer Vaccines
Immune Checkpoint Inhibitors
Immunotherapy
Prostate Cancer
Tumor Immune Evasion
Journal
Acta clinica Croatica
ISSN: 1333-9451
Titre abrégé: Acta Clin Croat
Pays: Croatia
ID NLM: 9425483
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
entrez:
3
1
2022
pubmed:
1
11
2019
medline:
1
11
2019
Statut:
ppublish
Résumé
First cancer vaccine that was approved for routine therapy was sipuleucel-T for treatment of patients with metastatic castration resistant prostate cancer. However, other immunotherapy drugs evaluated in prostate cancer, particularly immune checkpoint inhibitors, have failed to show therapeutic effect. There are several potential explanations for lack of response of prostate cancer to these drugs. These explanations, which are related to specific genetic (e.g. low mutational burden) and immunological (e.g. immunosuppressive tumor immune microenvironment) background of prostate cancer are discussed in this review. Also, new therapeutic strategies to overcome prostate cancer immunotherapy resistance and to select subgroups of patients that could benefit from immunotherapy are outlined.
Identifiants
pubmed: 34975203
doi: 10.20471/acc.2019.58.s2.13
pii: acc-58-supl-2-76
pmc: PMC8693557
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-81Références
Clin Cancer Res. 2007 Dec 1;13(23):6947-58
pubmed: 18056169
Int J Mol Sci. 2017 Jul 17;18(7):
pubmed: 28714919
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
J Leukoc Biol. 2017 Aug;102(2):393-406
pubmed: 28550116
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Mod Pathol. 2018 Oct;31(10):1539-1552
pubmed: 29849114
Cancer Immunol Immunother. 2013 Jan;62(1):137-47
pubmed: 22865266
J Clin Oncol. 2019 May 1;37(13):1051-1061
pubmed: 30817251
Transl Androl Urol. 2015 Jun;4(3):365-80
pubmed: 26814148
Curr Urol Rep. 2019 Sep 3;20(10):64
pubmed: 31482315
J Natl Cancer Inst. 2014 Sep 24;106(11):
pubmed: 25255802
Nature. 2018 Jul;559(7714):363-369
pubmed: 29950727
Clin Cancer Res. 2015 Aug 15;21(16):3619-30
pubmed: 25649018
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Eur Urol. 2016 Apr;69(4):693-703
pubmed: 26632144
Clin Cancer Res. 2018 Oct 1;24(19):4662-4671
pubmed: 29858218
Cancer. 2009 Aug 15;115(16):3670-9
pubmed: 19536890
J Clin Oncol. 2006 Jul 1;24(19):3089-94
pubmed: 16809734
J Clin Oncol. 2010 Mar 1;28(7):1099-105
pubmed: 20100959
J Natl Cancer Inst. 2017 Apr 1;109(4):
pubmed: 28376158
Urol Oncol. 2019 Aug;37(8):543-555
pubmed: 30446449
J Clin Oncol. 2017 Jan;35(1):40-47
pubmed: 28034081
Immunotherapy. 2019 Jul;11(10):903-912
pubmed: 31161846
JAMA Netw Open. 2019 Apr 5;2(4):e192589
pubmed: 31002323
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
JAMA Oncol. 2019 Apr 1;5(4):471-478
pubmed: 30589920
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Oncologist. 2019 Apr;24(4):430-432
pubmed: 30626711
J Urol. 2011 Sep;186(3):877-81
pubmed: 21788048
Oncoimmunology. 2015 Feb 25;4(4):e998538
pubmed: 26137416
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Oncotarget. 2018 Jun 19;9(47):28561-28571
pubmed: 29983880